- Home
- ZVRA
as of 02-12-2026 3:46pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | CELEBRATION |
| Market Cap: | 502.7M | IPO Year: | 2015 |
| Target Price: | $21.71 | AVG Volume (30 days): | 879.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.19 - $13.16 | Next Earning Date: | 03-10-2026 |
| Revenue: | $84,388,000 | Revenue Growth: | 244.60% |
| Revenue Growth (this year): | 333.64% | Revenue Growth (next year): | 44.19% |
| P/E Ratio: | 15.78 | Index: | N/A |
| Free Cash Flow: | -24230000.0 | FCF Growth: | N/A |
AI-Powered ZVRA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Zevra Therapeutics Inc. (ZVRA)
President and CEO
Avg Cost/Share
$8.56
Shares
14,625
Total Value
$125,185.61
Owned After
387,225
SEC Form 4
SVP, Finance & Corp Controller
Avg Cost/Share
$9.18
Shares
3,000
Total Value
$27,548.10
Owned After
29,590
SEC Form 4
CCO
Avg Cost/Share
$9.19
Shares
10,500
Total Value
$96,500.25
Owned After
62,278
SEC Form 4
President and CEO
Avg Cost/Share
$9.38
Shares
91,000
Total Value
$853,425.30
Owned After
387,225
SEC Form 4
SVP, Finance & Corp Controller
Avg Cost/Share
$8.82
Shares
1,750
Total Value
$15,442.00
Owned After
29,590
SEC Form 4
CCO
Avg Cost/Share
$8.83
Shares
3,375
Total Value
$29,800.24
Owned After
62,278
SEC Form 4
Chief Legal & Compliance
Avg Cost/Share
$8.83
Shares
4,080
Total Value
$36,009.67
Owned After
49,919
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$8.83
Shares
4,533
Total Value
$40,035.91
Owned After
9,723
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| McFarlane Neil F. | ZVRA | President and CEO | Feb 9, 2026 | Sell | $8.56 | 14,625 | $125,185.61 | 387,225 | |
| Sangiovanni Timothy J. | ZVRA | SVP, Finance & Corp Controller | Feb 3, 2026 | Sell | $9.18 | 3,000 | $27,548.10 | 29,590 | |
| Schafer Joshua | ZVRA | CCO | Feb 3, 2026 | Sell | $9.19 | 10,500 | $96,500.25 | 62,278 | |
| McFarlane Neil F. | ZVRA | President and CEO | Feb 2, 2026 | Sell | $9.38 | 91,000 | $853,425.30 | 387,225 | |
| Sangiovanni Timothy J. | ZVRA | SVP, Finance & Corp Controller | Jan 30, 2026 | Sell | $8.82 | 1,750 | $15,442.00 | 29,590 | |
| Schafer Joshua | ZVRA | CCO | Jan 30, 2026 | Sell | $8.83 | 3,375 | $29,800.24 | 62,278 | |
| Thompson Rahsaan | ZVRA | Chief Legal & Compliance | Jan 30, 2026 | Sell | $8.83 | 4,080 | $36,009.67 | 49,919 | |
| Quartel Adrian W | ZVRA | Chief Medical Officer | Jan 30, 2026 | Sell | $8.83 | 4,533 | $40,035.91 | 9,723 |
Compare ZVRA vs Leading Stocks
See how ZVRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.